Heat Biologics (HTBX) Reports 1st Patient Dosed in New Cohort of Expanded Phase 2 Trial of HS-110 in Combination with Merck's (MRK) KEYTRUDA in NSCLC Trial

January 14, 2019 8:15 AM EST Send to a Friend
Heat Biologics, Inc. (NASDAQ: HTBX) today announced that it has dosed its first patient in its Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login